A sweeping new review published in Discover Chemistry charts the remarkable rise of proteolysis-targeting chimeras, better known as PROTACs, from a bold theoretical idea to one of the most closely watched platforms in modern drug discovery. Written by Sandip G. Badadhe and colleagues, the comprehensive analysis traces how these unusual dual-headed molecules work at the molecular level, why they have succeeded where conventional inhibitors have failed, and what still stands between the laboratory and the pharmacy shelf. What emerges is a portrait of a technology that has already delivered clinical candidates for prostate cancer, breast cancer, and blood malignancies, while confronting formidable challenges in chemistry, pharmacokinetics, and manufacturing that will shape the next decade of development.
The fundamental insight behind PROTACs is deceptively simple: instead of blocking a disease-causing protein, destroy it outright. Classical small-molecule drugs operate through what pharmacologists call occupancy-driven inhibition, meaning they must remain bound to their target to exert effect. This strategy struggles against proteins that lack a well-defined binding pocket, even when those proteins are powerful drivers of disease. PROTACs sidestep the problem entirely by hijacking the ubiquitin-proteasome system, the cell’s own garbage disposal machinery. These heterobifunctional molecules carry two business ends, one ligand that grips the target protein and another that recruits an E3 ubiquitin ligase, connected by a chemical linker. When the chimera brings both proteins into proximity, the ligase tags the target with chains of ubiquitin, the universal molecular death mark, and the 26S proteasome chews the protein into peptides.
The mechanistic details matter enormously for drug design. The human genome encodes roughly two E1 ubiquitin-activating enzymes, about forty E2 conjugating enzymes, and more than six hundred E3 ligases, offering enormous untapped selectivity potential. Crucially, PROTAC action is catalytic rather than stoichiometric: a single degrader molecule can, in principle, drive the elimination of many copies of its target, dissociating after each degradation cycle to find another. But productive destruction depends on forming a stable three-body complex between target, degrader, and ligase, a property known as ternary complex cooperativity. Studies of the BRD4 degrader MZ1 using surface plasmon resonance and crystallography have shown that longer ternary complex residence time correlates with more efficient ubiquitination, and that high cooperativity allows MZ1 to selectively degrade BRD4 while sparing its close relatives BRD2 and BRD3. There is also a pharmacological quirk that developers must respect: at high concentrations, PROTACs can saturate either protein separately, collapsing ternary complex formation and paradoxically reducing degradation. This bell-shaped dose-response behavior, known as the hook effect, complicates dose selection in ways conventional inhibitors never face.
The design of these molecules is a delicate balancing act across three structural elements. Target ligands need not maximize binding affinity, since moderate affinity often suffices when the ternary complex is cooperative and geometrically productive, but they must tolerate the added bulk of a linker without losing selectivity. On the ligase side, cereblon, or CRBN, and von Hippel-Lindau, or VHL, dominate the field because high-quality ligands exist for both. CRBN recruiters derived from thalidomide, lenalidomide, and pomalidomide benefit from a favorable medicinal chemistry profile, while VHL ligands built around a stereochemically defined hydroxyproline core, exemplified by the nanomolar-affinity probe VH298, often deliver stable ternary complexes with fewer off-target effects on natural cereblon substrates. Emerging ligases including KEAP1, RNF114, and DCAF family proteins may eventually enable tissue-selective degradation, though most remain hampered by limited ligand availability and incomplete structural characterization. Linker engineering ties everything together: too short and the complex is strangled, too long and entropy penalties mount, and subtle modifications such as methyl substitution have been shown to improve oral absorption while preserving degradation efficiency.
Nowhere is the platform’s promise more visible than in oncology, where cancer cells’ dependence on a handful of overexpressed or mutant proteins makes them ideal targets for elimination. ARV-110, also known as bavdegalutamide, is an orally bioavailable androgen receptor degrader designed for metastatic castration-resistant prostate cancer patients who have stopped responding to conventional antagonists like enzalutamide. Early phase 1/2 data revealed encouraging activity in a molecularly defined subgroup: patients whose tumors carried AR mutations T878 or H875 showed a prostate-specific antigen fifty percent response rate of approximately forty-six percent. Yet the drug’s limitations are instructive, since it fails to degrade the common resistance variant AR-V7 or the L702H mutation, and gastrointestinal side effects such as nausea and diarrhea have accompanied its use. The lesson, the review emphasizes, is that clinical efficacy depends not only on degradation itself but on biomarker-guided patient selection rooted in the molecular subtype of each tumor.
On the breast cancer front, ARV-471, known as vepdegestrant, has advanced furthest of all PROTACs. Developed for ER-positive, HER2-negative advanced breast cancer, the molecule eliminates both wild-type and mutated estrogen receptors, including the notoriously difficult ESR1 mutations that drive endocrine resistance. Preclinical studies showed deeper ER knockdown than fulvestrant, the traditional selective estrogen receptor degrader, and clinical phase 1/2 results demonstrated robust activity with a manageable safety profile in heavily pretreated patients. Researchers identified 200 milligrams once daily as the optimal dose for balancing efficacy and tolerability, and the compound is now being evaluated in the global phase 3 VERITAC-2 trial, a milestone marking one of the first PROTACs to reach late-stage development for solid tumors. Published results in the New England Journal of Medicine have confirmed the approach’s clinical credibility.
Blood cancers have yielded another compelling success story. Bruton’s tyrosine kinase inhibitors such as ibrutinib frequently lose effectiveness when tumors acquire the C481 mutation, which prevents covalent binding to the kinase’s active site. BTK degraders work where inhibition fails because they do not depend on sustained occupancy of any single pocket; they remove the entire protein, abolishing both enzymatic activity and the oncogenic scaffolding functions that can persist even when the kinase is silenced. NX-2127, an oral cereblon-recruiting degrader, eliminates wild-type and C481-mutant BTK alike, and uniquely also degrades the immunomodulatory transcription factors IKZF1 and IKZF3, potentially amplifying anti-tumor efficacy through T-cell activation. Whether this dual action translates into durable benefit without excessive immunological toxicity remains an open question that ongoing trials must answer.
Beyond cancer, the review surveys emerging frontiers that could dramatically widen the platform’s reach. Neurodegenerative diseases are particularly attractive because they are driven by toxic, aggregation-prone proteins such as tau that may be better addressed by removal than inhibition, although the blood-brain barrier imposes punishing constraints on molecular size, polarity, and efflux susceptibility. Recent work with neurotransmitter-derived lipidoid nanoparticles carrying tau-targeting PROTAC-DNA nanocomplexes has promoted tau clearance and cognitive recovery in disease models. In immunology, degraders of IRAK4 and STAT family proteins promise cleaner modulation of inflammatory signaling than reversible inhibitors, and early clinical candidates such as KT-474 are already in testing. Meanwhile, photoactivatable PROTACs offer spatial and temporal control over degradation, antibody-directed delivery systems could solve tissue penetration problems, and macrocyclic degrader designs are shrinking the molecules’ daunting physicochemical footprint.
Substantial obstacles remain before targeted protein degradation can fulfill its promise. Most clinically investigated PROTACs occupy beyond-rule-of-five chemical space with molecular weights between roughly 700 and 1200 daltons, creating persistent difficulties with solubility, passive permeability, metabolic stability, and oral bioavailability. Resistance mechanisms are already appearing, including altered E3 ligase expression, impaired proteasome function, target protein mutations, and compensatory signaling pathways, prompting development of ligase-switching strategies, dual-target degraders, and rational combinations. Manufacturing is its own headache, since assembling two pharmacophores through a linker while preserving stereochemical purity complicates scale-up and inflates costs, argues for early integration of process chemistry and Quality-by-Design principles. Formulation science, from cyclodextrins to lipid nanoparticles and solid dispersions, is being marshaled to rescue otherwise marginal candidates. Artificial intelligence and machine learning are increasingly deployed for ternary complex prediction and linker selection, though docking scores alone cannot yet reliably forecast degradation efficiency and must be validated against biophysical measurements.
The overarching conclusion of the review is that PROTACs now constitute a genuinely distinct pharmacological modality whose success demands simultaneous optimization of ternary complex cooperativity, degrader pharmacokinetics, and tissue-selective ligase recruitment, rather than simple pursuit of binding affinity. The strongest clinical evidence remains concentrated in hormone-driven cancers, but the conceptual reach of the platform extends to proteins that traditional drugs simply could not touch. If the field can deliver ligandable E3 ligases beyond cereblon and VHL, predictable degradation through computational design, orally bioavailable degraders, and validated pharmacodynamic biomarkers that track target loss directly, targeted protein degradation may graduate from elegant chemical biology tool to a foundational pillar of twenty-first-century medicine.
Subject of Research: PROTAC-mediated targeted protein degradation for drug discovery and clinical development
Article Title: Proteolysis targeting chimeras for drug discovery from mechanistic basis to clinical translation
Article References: Proteolysis targeting chimeras for drug discovery from mechanistic basis to clinical translation. (n.d.). https://doi.org/10.1007/s44371-026-00963-4
Image Credits: AI Generated
DOI: 10.1007/s44371-026-00963-4
Keywords: PROTACs, targeted protein degradation, ubiquitin-proteasome system, E3 ligase, medicinal chemistry, bavdegalutamide, vepdegestrant, NX-2127, ternary complex cooperativity, hook effect, oncology drug development, beyond-rule-of-five
Cite Scienmag News
APA MLA Chicago
Bethany Barker. (September 12, 2026). PROTACs Move From Lab Concept to Clinical Reality in Targeted Protein Degradation. Scienmag. https://scienmag.com/protacs-move-from-lab-concept-to-clinical-reality-in-targeted-protein-degradation/
Bethany Barker. “PROTACs Move From Lab Concept to Clinical Reality in Targeted Protein Degradation.” Scienmag, 12 September 2026, https://scienmag.com/protacs-move-from-lab-concept-to-clinical-reality-in-targeted-protein-degradation/. Accessed 12 September 2026.
Bethany Barker. “PROTACs Move From Lab Concept to Clinical Reality in Targeted Protein Degradation.” Scienmag. September 12, 2026. https://scienmag.com/protacs-move-from-lab-concept-to-clinical-reality-in-targeted-protein-degradation/
Copy citation Download RIS
Tags: bavdegalutamidebeyond-rule-of-fivechallenges in PROTAC chemistry and pharmacokineticsclinical development of PROTACsdual-headed molecules for protein destructionE3 ligasefuture perspectives in targeted protein degradationhook effectinnovative approaches in drug developmentmanufacturing challenges for PROTACsmedicinal chemistrymodular design of PROTACsNX-2127oncology drug developmentovercoming limitations of traditional small-molecule inhibitorsprogress from laboratory research to clinical trialsPROTACsPROTACs for cancer therapyPROTACs in targeted protein degradationtargeted protein degradationternary complex cooperativityubiquitin-proteasome systemubiquitin-proteasome system in drug discoveryvepdegestrant
